Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
01/2011
01/12/2011CN101945650A Combination comprising a cannabinoid receptor binding compound and an opioid
01/12/2011CN101940789A Application of glucocorticoid to preparing medicament for treating tardive hemorrhagic cystitis
01/12/2011CN101940788A Application of antidepressant in treatment of stress gastric ulcer
01/12/2011CN101940551A Self-assembly nano-particles of sulfhydrylation chitosan quaternary ammonium salt and preparation method and application thereof
01/12/2011CN101612401B Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
01/12/2011CN101327182B Preparation of nano crystal fibre felt of water-insoluble medicament
01/11/2011US7868042 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; for improving renal function; nitric oxide synthase modulators; hypotensive agents
01/11/2011US7868040 Anti-cancer combinations
01/11/2011US7868039 Anti-cancer combinations
01/11/2011US7867986 Enhanced drug delivery in transdermal systems
01/11/2011US7867764 replication-defective recombinant adenovirus comprising a heterologous nucleic acid sequence encoding an antigenic determinant of Plasmodium falciparum that comprises an immunogenic peptide of the circumsporozoite protein; viral vectors
01/11/2011US7867518 Controlled release compositions for interferon based on PEGT/PBT block copolymers and method for preparation thereof
01/11/2011US7867509 Fast dissolving orally consumable films
01/11/2011US7867508 administering a decongestant(oxymetazoline hydrochloride), a corticosteroid (triamcinolone acetate) and anticholinergic agent ipratropium bromide for nonaddictive treatment of upper respiratory conditions in man and animals, e.g., allergic, non-allergic and mixed rhinitis in man or pharyngitis in horses
01/11/2011US7867498 comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides; for use in treatment and prevention of plasmodial infection; genetic vaccines; for immunization
01/11/2011US7867481 Method of treating anemia by administering IL-1ra
01/11/2011CA2472149C New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments
01/11/2011CA2460696C Use of substituted aminomethyl chromans for the treatment of extrapyramidal movement disorders
01/11/2011CA2453996C Injectable pharmaceutical formulations
01/11/2011CA2436891C Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
01/11/2011CA2429781C Linkable sialyl lewis x analogs
01/11/2011CA2400486C Aniline-derived ligands for the thyroid receptor
01/11/2011CA2378883C Methods of reducing microbial resistance to drugs
01/11/2011CA2374039C Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
01/11/2011CA2349406C Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
01/06/2011WO2011002606A1 Methods of identifying a patient population eligible for treatment with nitric oxide via inhalation
01/06/2011WO2011002026A1 Amyloid fibril formation inhibitor and use thereof
01/06/2011WO2011001440A1 Pharmaceutical compositions of valsartan
01/06/2011WO2011000930A1 L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin
01/06/2011WO2010081825A3 Pirenzepine as an agent in cancer treatment
01/06/2011WO2010056985A8 Treatment of proteinopathies using a farnesyl transferase inhibitor
01/06/2011US20110003764 Methods for Treatment of HIV or Malaria Using Combinations of Chloroquine and Protease Inhibitors
01/06/2011US20110003746 Protein variants
01/06/2011US20110003388 processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient; making an enhanced, autologous fat graft comprising supplementing a first portion of extracted adipose tissue with an additive and a disaggregated population of adipose-derived cells
01/06/2011US20110002983 Compound
01/06/2011US20110002957 Hapten-carrier conjugates for treating and preventing nicotine addiction
01/06/2011US20110002946 Immunostimulatory Combinations
01/06/2011US20110002910 Therapeutic agents comprising pro-apoptotic proteins
01/06/2011US20110002887 Combinations of antibodies selective for dr5 and other therapeutic agents
01/06/2011CA2766706A1 L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin
01/06/2011CA2753290A1 Topical skin treatment kits
01/05/2011EP2270131A1 Feline probiotic lactobacilli
01/05/2011EP2270107A1 Compounds for Dual Photodiagnosis and Therapy
01/05/2011EP2270052A2 Antibodies to OPGL
01/05/2011EP2269694A2 Antituberculous composition comprising oxazole compounds
01/05/2011EP2269656A2 Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
01/05/2011EP2269654A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
01/05/2011EP2269649A2 Compositions containing a capillary active system with application-related differentiability, and the use thereof
01/05/2011EP2269648A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics
01/05/2011EP2269647A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics
01/05/2011EP2269646A1 Prophylactic or therapeutic agent for diabetes or obesity
01/05/2011EP2269632A2 Immunostimulatory compositions and methods of stimulating an immune response
01/05/2011EP2269628A2 Pancreas-specific proteins
01/05/2011EP2269620A1 Therapeutic uses of dunaliella powder
01/05/2011EP2269606A2 Transdermal analgesic systems having reduced abuse potential
01/05/2011EP2269604A1 Treatment of solid tumours with rapamycin derivatives
01/05/2011EP2269603A1 Treatment of solid tumours with rapamycin derivatives
01/05/2011EP2269602A1 Antibiotic compositions for treatment of the eye, ear and nose
01/05/2011EP2269598A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
01/05/2011EP2269596A2 Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
01/05/2011EP2269590A2 Ion binding polymers and uses thereof
01/05/2011EP2269589A2 Ion binding polymers and uses thereof
01/05/2011EP2269579A2 Tamper-resistant products for opioid delivery
01/05/2011EP2268312A2 Treatment of intervertebral disc degeneration
01/05/2011EP2268299A1 Compositions and method for reducing scar formation in wound healing
01/05/2011EP2268279A1 Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl¨-3-oxoisoindoline-4-yl}carboxamide
01/05/2011EP2029139B1 Use of a p38 kinase inhibitor for treating psychiatric disorders
01/05/2011EP2016950B1 Pharmaceutical composition comprising an exendin-4 peptide
01/05/2011EP1908467B1 Agent for treating herpesvirus-derived pain
01/05/2011EP1771551B1 Novel cell populations and uses thereof
01/05/2011EP1750862B1 Pharmaceutical composition containing irbesartan
01/05/2011EP1750667B1 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
01/05/2011EP1619498B1 Method of screening remedy for heart disease and medicinal composition for treating heart disease
01/05/2011EP1558256B1 Pyrroloquinoline quinone and a beta blocker for the treatment of ischemia or reperfusion injury
01/05/2011EP1546182B1 Compositions and methods for the diagnosis and treatment of tumor
01/05/2011EP1493034B1 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity
01/05/2011EP1465637B1 25-hydroxy vitamin d3 compositions
01/05/2011EP1463806B1 Novel cyclooxygenase variants and methods of use
01/05/2011EP1437043B1 Rat model with overexpression of regucalcin
01/05/2011EP1365778B1 Treating pulmonary disorders with gaseous agent causing repletion of gsno
01/05/2011EP1294769B1 Antibodies that immunospecifically bind to blys
01/05/2011EP1128814B1 Aerosols comprising nanoparticle drugs
01/05/2011CN101939329A Amino acid pairing-based self assembling peptides and methods
01/05/2011CN101939026A Antibacterial combination therapy
01/05/2011CN101939025A Therapeutic agent for pruritus
01/05/2011CN101939022A Methods for treating obesity and obesity related diseases and disorders
01/05/2011CN101939017A Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
01/05/2011CN101939001A Combination comprising paclitaxel for treating ovarian cancer
01/05/2011CN101935673A Method for promoting liver regeneration by adjusting GAT-1 expression
01/05/2011CN101934078A Pharmaceutical composition comprising drospirenone and estrogen, and application thereof
01/05/2011CN101934070A Veterinary antibacterial drug composition containing lysozyme and oligosaccharide and application thereof
01/04/2011US7863322 Anti-cancer combinations
01/04/2011US7863321 Anti-cancer combinations
01/04/2011US7863320 Synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan
01/04/2011US7863287 Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
01/04/2011US7863261 androgen receptor modulator; analogs of androst-5-ene-3 beta ,17 beta -diol ("AED") or 1,3,5(10)-estratriene-17 alpha -ethynyl-3 beta ,17 beta -diol ("EED")
01/04/2011US7863254 Administering cytosine-containing or cytidine-containing compound, creatine- containing compound, adenosine-containing, or adenosine- elevating compound; e.g., CDP, CDP-choline, S-adenosylmethionine) or triacetyluridine
01/04/2011US7863241 Lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction; for example protease inhibitors; treating inflammatory lung conditions such as asthma, chronic obstructive pulmonary disease
01/04/2011US7862831 Priming extracellular matrix by treating with a priming agent; adding to the primed extracellular matrix a solution of a polymerizable agent; reacting the primed extracellular matrix and polymerizable agent to create a hydrogel covalently bound to the extracellular matrix
01/04/2011US7862829 Enhance immunology response ti immunogen; alpha virus adjuvant or Venezuelan Equine Encephalatis virua adjuvants